BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 32671117)

  • 21. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
    Girotti MR; Saturno G; Lorigan P; Marais R
    Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Immunology of Melanoma.
    Ko JS
    Clin Lab Med; 2017 Sep; 37(3):449-471. PubMed ID: 28802495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanoma immunotherapy: strategies to overcome pharmacological resistance.
    Trojaniello C; Vitale MG; Scarpato L; Esposito A; Ascierto PA
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):289-304. PubMed ID: 32195606
    [No Abstract]   [Full Text] [Related]  

  • 28. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
    Luke JJ; Ott PA
    Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A role of immunotherapy in metastatic malignant melanoma.
    Allen T; Gundrajakuppam L
    Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for Melanoma.
    Albittar AA; Alhalabi O; Glitza Oliva IC
    Adv Exp Med Biol; 2020; 1244():51-68. PubMed ID: 32301010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
    Naderi-Azad S; Sullivan R
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
    [No Abstract]   [Full Text] [Related]  

  • 32. Systemic Therapy Options for Patients With Unresectable Melanoma.
    Yushak M; Chapman P; Robert C; Kudchadkar R
    Am Soc Clin Oncol Educ Book; 2017; 37():661-672. PubMed ID: 28561662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinatorial approach to treatment of melanoma.
    Ashworth MT; Daud AI
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous melanoma and the immunotherapy revolution (Review).
    Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M
    Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cell receptor therapy against melanoma-Immunotherapy for the future?
    Winge-Main AK; Wälchli S; Inderberg EM
    Scand J Immunol; 2020 Oct; 92(4):e12927. PubMed ID: 32640053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Surgery in Combination with Immunotherapy.
    Klemen ND; Shindorf ML; Sherry RM
    Surg Oncol Clin N Am; 2019 Jul; 28(3):481-487. PubMed ID: 31079801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Schummer P; Schilling B; Gesierich A
    Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for advanced melanoma: fulfilling the promise.
    Gogas H; Polyzos A; Kirkwood J
    Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.